CARB-X supports BioVersys in the fight against antimicrobial resistance with up to almost 9 million dollars
BioVersys receives CARB-X Award of up to US$ 8.92 Million for Development of Novel Antimicrobial Therapies:
Kinarus presents plans for a drug against Long Covid
POLYNEURON AND UNIVERSITY OF BASEL AWARDED GRANT OF CHF 1.2M...
Virtual Auditorium Event: How strained Switzerland – EU re...
Bottmedical secures CHF 1.1 million to prepare Swiss market ...
BioVersys receives €20 million in EU financing to support ...